What is the appropriate starting dose of leucovorin for a 13-year-old male weighing 92 lb (≈42 kg)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Leucovorin Starting Dosage for 13-Year-Old Male, 92 lbs

For this 13-year-old male weighing 42 kg (92 lbs), the starting dose of leucovorin is 15 mg/m² every 6 hours by IV or IM injection, which translates to approximately 20-22 mg per dose based on an estimated body surface area of 1.4 m². 1

Context-Dependent Dosing Algorithm

The appropriate leucovorin dose depends critically on why this patient is receiving it:

For High-Dose Methotrexate (HDMTX) Rescue

Initial dosing:

  • Standard starting dose: 15 mg/m² IV or IM every 6 hours 1
  • For a 42 kg adolescent with BSA ~1.4 m²: approximately 21 mg per dose
  • Timing: Start 24 hours after methotrexate infusion begins (for rapid infusion <6 hours) or 36-44 hours after start (for 24-hour infusion regimen) 1
  • Route: IV or IM only—avoid oral administration due to chemotherapy-induced GI dysfunction and decreased bioavailability 1

Dose adjustment based on methotrexate levels at 42-48 hours:

The 2022 Chinese Pharmacological Society guideline provides a clear escalation strategy 1:

  • MTX 0.2-1.0 μmol/L: Continue 15 mg/m² q6h (~21 mg per dose)
  • MTX 1.0-2.0 μmol/L: Increase to 30 mg/m² q6h (~42 mg per dose)
  • MTX 2.0-3.0 μmol/L: Increase to 45 mg/m² q6h (~63 mg per dose)
  • MTX 3.0-4.0 μmol/L: Increase to 60 mg/m² q6h (~84 mg per dose)
  • MTX 4.0-5.0 μmol/L: Increase to 75 mg/m² q6h (~105 mg per dose)
  • MTX >5.0 μmol/L: Dose = MTX concentration × weight in kg, q6h

The FDA label corroborates this approach, specifying 15 mg every 6 hours for normal methotrexate elimination, with escalation to 150 mg every 3 hours for delayed early elimination 2.

For Methotrexate Overdose or Impaired Elimination

Start immediately with 10 mg/m² (~14 mg) IV, IM, or PO every 6 hours until serum methotrexate <10⁻⁸ M 2. If 24-hour creatinine increases ≥50% or methotrexate levels remain dangerously elevated, escalate to 100 mg/m² (~140 mg) IV every 3 hours 2.

Critical Safety Considerations

Do NOT administer leucovorin intrathecally—this is explicitly contraindicated 2.

Infusion rate limits: When single doses exceed 160 mg, infuse over at least 1 hour to avoid calcium-related complications 2. For this patient's weight, this becomes relevant only at the highest rescue doses.

Monitoring requirements:

  • Measure serum creatinine and methotrexate levels at least daily 2
  • Continue leucovorin until methotrexate <0.05-0.2 μmol/L 1
  • Monitor liver and kidney function throughout rescue 1
  • Maintain urine pH ≥7.0 with hydration and alkalinization 2

Evidence Quality and Strength

The 2022 guideline from the British Journal of Clinical Pharmacology provides the most comprehensive, recent evidence for pediatric dosing 1. This is a strong recommendation based on low-quality evidence for the initial 15 mg/m² dose, with systematic review of 4 studies showing no difference in toxicity compared to higher doses (20-30 mg/m²). The dose adjustment strategy based on methotrexate levels is a weak recommendation based on expert opinion, adapted from pediatric ALL protocols.

The FDA label supports these recommendations but provides less granular guidance for dose escalation 2.

Common pitfall: Starting leucovorin too early antagonizes methotrexate's chemotherapeutic effect 1. Conversely, delaying beyond recommended timeframes increases toxicity risk. Adhere strictly to the timing protocols based on methotrexate infusion duration.

Formulation consideration: Use parenteral formulations exclusively during active chemotherapy due to GI toxicity and unreliable oral absorption 1. The evidence for autism treatment 3, 4 is irrelevant to this clinical scenario and should be disregarded.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.